Halo Therapeutics is now enrolling patients in our initial clinical trial of HT-100 for Duchenne muscular dystrophy. For more information about participating in the HT-100 clinical program, please contact us at trialinfo@halotherapeutics.com. For a description of our first clinical trial, please visit clinicaltrials.gov.